Literature DB >> 24359127

Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.

R Sinha1, K Lecamwasam, K Purshouse, J Reed, M R Middleton, L Fearfield.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24359127     DOI： 10.1111/bjd.12796

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

Review 1.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

Review 2.  Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors:  Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

Review 3.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 4.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

Review 5.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.